Results 221 to 230 of about 547,450 (338)

The chromatin remodeler LET-418/Mi-2 regulates the intracellular pathogen response in the C. elegans intestine. [PDF]

open access: yesBMC Genomics
Rajopadhye S   +5 more
europepmc   +1 more source

Chromatin remodeler Activity-Dependent Neuroprotective Protein (ADNP) contributes to syndromic autism. [PDF]

open access: yesClin Epigenetics, 2023
D'Incal CP   +10 more
europepmc   +1 more source

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity

open access: yesAdvanced Science, EarlyView.
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu   +8 more
wiley   +1 more source

UMSBP2 is chromatin remodeler that functions in regulation of gene expression and suppression of antigenic variation in trypanosomes. [PDF]

open access: yesNucleic Acids Res, 2023
Soni A   +10 more
europepmc   +1 more source

The ITGB2‐COPS3‐SOX2 Axis and SOX2 Liquid‐Liquid Phase Separation: Dual Mechanisms Governing Osteosarcoma Stemness

open access: yesAdvanced Science, EarlyView.
Osteosarcoma stemness is driven by the ITGB2‐COPS3‐SOX2 signaling axis. This study reveals that nuclear COPS3 stabilizes SOX2, which in turn undergoes liquid‐liquid phase separation to promote stemness. Based on this mechanism, a novel COPS3 inhibitor, Z‐5891, was developed, effectively suppressing tumor growth and stemness in vivo, offering a ...
Lei Guo   +7 more
wiley   +1 more source

Redistribution of the chromatin remodeler Brg1 directs smooth muscle-derived adventitial progenitor-to-myofibroblast differentiation and vascular fibrosis. [PDF]

open access: yesJCI Insight, 2023
Jolly AJ   +10 more
europepmc   +1 more source

CD28‐Targeted Enzyme‐Responsive Conformation‐Switching Peptide Self‐Assembly for Selective T‐Cell Acute Lymphoblastic Leukemia (T‐ALL) Therapy

open access: yesAdvanced Science, EarlyView.
We developed the enzyme‐responsive peptide SAp‐CD28 to selectively target CD28‐overexpressing T‐ALL cells. Following phosphatase‐mediated activation, SAp‐CD28 undergoes conformational switching and nanooligomerization, resulting in the disruption of CD28 downstream signaling.
Jun Li   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy